Merkel Cell Carcinoma: Symptoms, Causes, Diagnosis & Treatment

Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer. That description matters, it’s genuinely important not to confuse MCC with the skin cancers most people have heard of:

• MCC is not melanoma
• MCC is not basal cell carcinoma
• MCC is not squamous cell carcinoma

MCC is far less common than these other skin cancers, but it can behave more aggressively — it often grows faster and has a meaningfully higher chance of spreading to lymph nodes and distant organs. It typically develops in sun-exposed skin and is most often diagnosed in older adults, though it can occur in people with otherwise healthy immune systems as well as those who are immunosuppressed.

Because appearance alone can look similar to several other, much more common skin conditions, a biopsy is always required to confirm the diagnosis. Early diagnosis and accurate staging genuinely matter for this cancer, which is a large part of why this guide exists — to help you understand what happens after a suspicious lesion is found, not to diagnose one.

What Does Merkel Cell Carcinoma Look Like?

MCC most often appears as a firm, painless, rapidly growing skin nodule — it can be red, pink, purple, bluish, or flesh-colored, and is most commonly found on sun-exposed areas like the head, neck, and arms, though it can occur elsewhere.

Typical features that may raise suspicion include a nodule that is:

• Firm to the touch
• Usually painless
• Growing noticeably over weeks, not months or years
• Red, pink, purple, violaceous (bluish-purple), or simply flesh-colored
• Located most often on the head, neck, or arms — sun-exposed skin generally

It’s genuinely important to say this plainly: appearance alone cannot diagnose MCC. Many far more common, benign skin conditions can look similar. What tends to prompt evaluation isn’t any single color or shape, but the combination of a new, firm, rapidly enlarging, painless nodule especially in an older adult or someone who is immunosuppressed.

Symptoms and Warning Signs

Beyond the primary skin nodule itself, features that warrant prompt medical evaluation include:

• Rapid growth over a period of weeks
• A firm texture that doesn’t change with pressure
• Painlessness (though some lesions can eventually become tender, especially if they ulcerate)
• A genuinely new nodule, not a longstanding mole or skin tag that hasn’t changed
• Color change over time
• Bleeding or ulceration of the lesion
• Enlarging lymph nodes near the site (for example, in the neck, armpit, or groin, depending on lesion location)

None of these symptoms, individually or together, prove MCC — they’re reasons to have a suspicious lesion evaluated by a dermatologist, not a self-diagnosis checklist.

AEIOU: A Clinical Memory Aid, Not a Diagnosis

AEIOU is a memory aid clinicians sometimes use to recall common features associated with MCC. It is not a diagnostic test, and having several or even all of these features does not confirm MCC — nor does lacking some of them rule it out.

This tool exists to help clinicians remember which features are commonly associated with MCC — it’s a prompt for suspicion and referral, not a checklist that confirms or excludes the diagnosis. Plenty of confirmed MCC cases don’t fit every letter of this pattern (for example, MCC does occur in people under 50 and in people without significant sun exposure history), and plenty of lesions that fit the pattern turn out to be something else entirely on biopsy.

Causes and Risk Factors

Most MCC cases are linked to one of two major contributing factors — infection with Merkel cell polyomavirus, or cumulative UV radiation exposure — though most patients don’t have one single identifiable “cause” in the way an infection or injury might have a clear trigger.

Evidence-supported risk factors include:

• Older age — most patients are diagnosed after age 50
• Immunosuppression — including solid-organ transplant recipients, people with certain hematologic malignancies (like chronic lymphocytic leukemia), and people living with HIV
• Chronic UV exposure — cumulative sun exposure over time, particularly relevant to virus-negative MCC
• Fair skin
• Merkel cell polyomavirus infection — discussed in detail below

It’s worth stating clearly: most people who develop MCC don’t have a single, identifiable cause — it typically reflects some combination of these factors rather than one specific event or exposure. It’s also worth saying directly, for anyone reading this while managing an immunosuppressive condition or after a transplant: an elevated risk associated with immunosuppression is not something to feel any sense of blame about — it reflects how these medications and conditions affect immune surveillance broadly, not anything about individual choices.

Merkel Cell Polyomavirus and MCC

Merkel cell polyomavirus (MCPyV) is associated with a substantial proportion of MCC cases, particularly in certain populations, through viral integration into tumor cell DNA. However, having MCPyV infection does not mean a person has or will develop cancer — this is a very common virus, and only a small fraction of people who carry it will ever develop MCC.

Key points to understand:

• MCPyV is a common virus that most adults are exposed to at some point, typically without any symptoms or consequences
• In MCC tumor cells, viral DNA is often found integrated into the cell’s genome, contributing to tumor development in a meaningful proportion of cases
• Virus-positive and virus-negative MCC are somewhat biologically distinct — virus-negative tumors are more strongly associated with cumulative UV damage and tend to carry a different pattern of genetic mutations
• The relative proportion of virus-positive versus virus-negative MCC varies across different studied populations and geographic regions

What this does not mean: a positive MCPyV test on its own does not diagnose cancer, and testing positive for this virus in the general population is not a cause for alarm — it reflects an extremely common, usually harmless viral exposure. The clinical relevance of MCPyV testing arises specifically in the context of an already-diagnosed or strongly suspected MCC tumor, where it can add information about disease biology.

When to See a Doctor

A new, firm, persistent, rapidly enlarging, and typically painless skin lump — particularly in someone older than 50 or with a weakened immune system — should be evaluated by a dermatologist rather than watched and waited on.

Particularly concerning features that warrant a prompt appointment:

• Rapid growth over weeks
• Firmness
• A lesion that doesn’t hurt but keeps growing
• Any new, unexplained skin nodule that doesn’t resolve
• Color changes
• Bleeding or ulceration
• Nearby lymph nodes that seem enlarged

To be clear about what this section is and isn’t: this is guidance about when to seek evaluation, not a suggestion that any specific lesion you may be noticing is MCC. The overwhelming majority of new skin lumps are not MCC but because early evaluation genuinely matters for outcomes if it does turn out to be, prompt assessment rather than a “wait and see” approach is the reasonable path for a lesion with these features.

How Merkel Cell Carcinoma Is Diagnosed

Diagnosis requires a tissue biopsy — there is no blood test, scan, or visual exam alone that can confirm MCC. The diagnostic pathway typically moves from physical examination through biopsy, pathology confirmation, and then staging evaluation.

General diagnostic pathway:

1. Physical examination of the lesion and nearby lymph nodes
2. Dermoscopy, where appropriate, as an adjunct to clinical assessment (not a substitute for biopsy)
3. Skin biopsy — the essential step that confirms diagnosis
4. Histopathology and immunohistochemistry — detailed microscopic and molecular analysis of the biopsy tissue
5. Lymph node evaluation, including sentinel lymph node biopsy where appropriate
6. Imaging for staging, when clinically indicated

A biopsy is required to confirm Merkel cell carcinoma. No combination of appearance, growth pattern, or risk factors can substitute for tissue diagnosis — this is one of the clearest, most consistent points across dermatologic oncology guidance on this cancer.

Biopsy and Pathology

Types of biopsy that may be used, depending on the clinical situation:

• Punch biopsy
• Excisional biopsy
• Incisional biopsy

The choice depends on lesion size, location, and clinical judgment about what will provide adequate tissue — this decision is made by your treating clinician, not something to research and request specifically yourself. Obtaining adequate tissue matters not just for the initial diagnosis, but for the immunohistochemistry and pathologic assessment that follow.

What pathology typically shows in MCC:

• A “small round blue-cell” appearance under the microscope — a pattern shared with several other rare tumor types, which is exactly why additional testing matters
• Features consistent with neuroendocrine differentiation
• Cytokeratin 20 (CK20) positivity, often in a characteristic perinuclear dot-like pattern, in many (though not all) cases
• Positivity for neuroendocrine markers such as synaptophysin

An important nuance: CK20 positivity is a commonly seen and clinically useful feature, but it is not an absolute requirement for diagnosis — some MCCs, including certain molecular subtypes, can show different immunophenotypes. This is exactly why pathology diagnosis of MCC relies on a panel of features and expert interpretation, not any single marker in isolation.

Differential diagnosis — conditions MCC can resemble on initial appearance or even on some pathology features, requiring careful distinction:

• Basal cell carcinoma
• Squamous cell carcinoma
• Melanoma
• Lymphoma
• Cutaneous metastasis from another cancer
• Adnexal (skin gland-related) tumors
• Other neuroendocrine tumors

This is why pathology and immunohistochemistry not appearance are what ultimately distinguish MCC from these other conditions.

Sentinel Lymph Node Biopsy and Nodal Evaluation

Sentinel lymph node biopsy (SLNB) is commonly considered for MCC patients whose lymph nodes feel normal on examination, because microscopic disease can be present in lymph nodes even when they appear and feel completely normal.

Lymph node evaluation may involve:

• Physical examination of nearby node regions
• Ultrasound, where appropriate, to assess for suspicious nodes
• Sentinel lymph node biopsy (SLNB) — a procedure that identifies and samples the first node(s) a tumor would drain to, done for clinically node-negative patients
• Fine-needle aspiration or core biopsy, when a lymph node is already clinically suspicious
• Imaging, discussed further below

Why SLNB matters specifically in MCC: because this cancer has a meaningful rate of spreading microscopically to lymph nodes before that spread is detectable by exam or imaging, SLNB plays an important role in accurate staging, prognosis, and treatment planning — findings from this procedure can change the recommended treatment plan.

Important nuance: SLNB is not automatically appropriate or feasible for every patient — factors like prior surgery in the area, certain anatomic locations, or other individual circumstances can affect whether it’s recommended or how it’s approached. This is a decision made by your surgical team based on your specific case, not a universal step for everyone.

Imaging

Depending on stage, symptoms, and clinical circumstances, staging imaging may include:

Imaging is not automatically required for every patient at every stage — for example, early localized disease may not warrant extensive imaging, while more advanced or symptomatic disease typically does. It’s also worth understanding that imaging cannot exclude microscopic nodal disease the way sentinel lymph node biopsy can — the two serve different, complementary purposes rather than one replacing the other.

Merkel Cell Carcinoma Staging

MCC is staged using the AJCC (American Joint Committee on Cancer) 8th edition staging system, based on primary tumor size, regional lymph node involvement, and distant metastasis. Broadly: Stage I and II are localized to the skin (differing mainly by tumor size), Stage III involves regional lymph nodes, and Stage IV represents distant metastatic disease.

A few clinically important nuances worth understanding:

• Clinical staging and pathologic staging can differ. Clinical staging is based on exam and imaging; pathologic staging incorporates actual tissue findings (like sentinel node biopsy results), and is generally considered more precise once available.
• A finding specific to MCC’s staging history: patients with lymph node involvement but no identifiable primary tumor (“unknown primary”) are staged as a distinct category from those with both a known primary tumor and nodal disease, because research has shown these two situations carry meaningfully different outlooks.
• Not every patient develops distant metastases — the majority of patients present with localized or regionally-confined disease at diagnosis, not Stage IV disease.

Staging is not just an academic label — it directly shapes whether radiation is recommended, whether systemic therapy is considered, and what surveillance schedule makes sense going forward.

Merkel Cell Carcinoma Treatment Overview

Treatment depends on the stage, tumor size and location, surgical margins, lymph-node involvement, immune status, and overall health. Options may include:

• Surgery – usually the main treatment for localized MCC.
• Radiation therapy – commonly used after surgery or when surgery isn’t suitable.
• Immunotherapy – a key treatment for advanced or metastatic MCC.
• Chemotherapy – used selectively, particularly when immunotherapy isn’t appropriate.

Surgery

Localized MCC is generally treated with wide local excision, followed by assessment of surgical margins. Sentinel lymph node biopsy is often performed to check for microscopic spread. Depending on lymph-node findings, treatment may include observation, lymph-node surgery, or radiation.

Radiation Therapy

MCC is highly radiosensitive, making radiation an important treatment option. It may be used:

• After surgery to reduce recurrence risk
• As the primary treatment when surgery isn’t suitable
• For regional lymph-node disease
• For unresectable tumors
• To relieve symptoms from advanced disease

Immunotherapy

Checkpoint inhibitors have become central to advanced MCC treatment. Approved options vary by country and may include avelumab, pembrolizumab, and retifanlimab. Treatment choice depends on previous therapy, overall health, immune status, and other individual factors.

Immunotherapy can cause immune-related side effects affecting organs such as the skin, thyroid, liver, lungs, or colon, so new symptoms should be reported promptly.

Chemotherapy

Chemotherapy is no longer generally the preferred first-line treatment for advanced MCC when immunotherapy is appropriate. It may still be considered for rapidly progressing disease, patients unsuitable for immunotherapy, or selected later-line situations.

Metastatic and Recurrent MCC

Stage IV disease may involve distant lymph nodes, skin, lungs, liver, bones, or other organs. Treatment can include immunotherapy, radiation, selected surgery, chemotherapy, or clinical trials.

Recurrence may be local, regional, or distant. Treatment is reassessed based on the location, previous treatment, and overall disease status.

Prognosis and Follow-Up

Outcomes depend strongly on stage, tumor size, lymph-node involvement, immune status, and treatment response. Regular skin examinations, lymph-node checks, imaging when appropriate, and monitoring for new symptoms are important because recurrence risk is highest during the first few years after treatment.

Merkel Cell Carcinoma vs. Other Skin Cancers

MCC vs. Melanoma

MCC vs. Basal Cell Carcinoma (BCC) vs. Squamous Cell Carcinoma (SCC)

Neither of these comparisons is meant to suggest one skin cancer type is universally “worse” than another — each carries its own typical behavior, and your specific pathology result is what matters for your individual case, not a general ranking.

Merkel Cell Carcinoma Treatment Cost in India

There is no single price for MCC treatment in India — cost depends on which combination of surgery, radiation, and immunotherapy your specific case requires, and can only be reasonably estimated after your pathology and staging information have been reviewed by an oncology team.

Rather than presenting an invented package price, here’s what actually drives total cost:

Why costs vary so significantly by category: a patient with early, localized Stage I disease requiring only surgery faces a very different total cost than a patient with metastatic disease requiring extended immunotherapy — presenting one number for “MCC treatment in India” would be genuinely misleading given how differently these situations are managed. What we can offer is a personalized estimate once your pathology and staging information have been reviewed, which is meaningfully more useful than a generic figure.

Considering India for Treatment

Because MCC is rare, having access to a center with genuine, specific experience in this cancer — not just general dermatologic oncology — matters more than it might for a more common skin cancer. India offers relevant infrastructure at accredited cancer centers, including dermatologic and surgical oncology, medical oncology, radiation oncology, dermatopathology with immunohistochemistry capability, PET/CT access, and availability of the immunotherapy agents discussed above where regulatory approval allows.

This is not a claim that India is automatically “the best” option for MCC — the right choice depends on your specific stage, which specific treatments (particularly which immunotherapy agent, given the regulatory differences discussed above) your case may need, and practical considerations around travel and follow-up. Worth specifically comparing, wherever you’re considering treatment:

• Whether the center has genuine, demonstrable experience with MCC specifically, given how rare this cancer is
• Whether the specific immunotherapy agents your case may benefit from are actually available and regulatorily approved for use in that country
• Pathology capability, specifically for the immunohistochemistry markers relevant to MCC diagnosis
• Multidisciplinary coordination between surgery, radiation oncology, and medical oncology, given how frequently MCC treatment involves more than one modality

Choosing a Merkel Cell Carcinoma Treatment Center

Rather than a “top hospitals” list, here’s what a center genuinely equipped for MCC care should have:

• A dermatologic oncologist or experienced surgical oncologist with specific familiarity treating MCC, not only general skin cancer experience
• Medical oncology with experience in immunotherapy management, including managing immune-related side effects
• Radiation oncology, given how central radiation often is to MCC treatment
• Dermatopathology with immunohistochemistry capability, including markers relevant to MCC diagnosis
• PET/CT access
• Multidisciplinary tumor board coordination between these specialties
• ICU support, where needed for more complex cases
• Clinical trial access, where relevant, given how actively this field continues to evolve

If a facilitator or hospital website makes broad “best hospital” claims without being able to speak to specific MCC case experience, that’s worth treating as a prompt to ask more specific questions, not less.

International Patient Treatment Journey

1. Share pathology and medical reports for initial oncology review
2. Review of biopsy and pathology findings
3. Confirmation of diagnosis
4. Staging of the disease, including any needed additional imaging or sentinel node evaluation
5. Specialist opinions, drawing on dermatologic/surgical oncology, medical oncology, and radiation oncology
6. Development of an individualized treatment plan
7. Hospital selection, based on what your specific plan requires
8. Cost estimate, based on your actual treatment plan
9. Medical visa guidance
10. Travel and accommodation planning
11. Treatment — surgery, radiation, and/or systemic immunotherapy as planned
12. Response monitoring
13. Follow-up planning
14. Return-home coordination for ongoing surveillance

This process cannot guarantee diagnosis outcome, visa approval, treatment response, cure, exact cost, or survival — no legitimate source can guarantee any of these, and any that do should be treated with real skepticism.

Frequently Asked Questions